A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer.

Polymorphisms in the N-acetyltransferase 2 (NAT2) gene are determinants of the rate of metabolic activation of carcinogenic compounds such as aryl aromatic amines. Homozygosity for any combination of three variant alleles in Caucasians defines 'slow' acetylators; presence of one or two wild-type alleles characterizes 'rapid' acetylators. Although most previous studies have not observed an overall elevation in risk of breast cancer among slow acetylators, a recent study observed that cigarette smoking was associated with a large increase in risk of breast cancer among slow acetylators. We assessed the relation between NAT2 acetylation status and breast cancer risk, and its interaction with smoking, in a prospective study of mainly Caucasian US women. Four hundred and sixty-six incident cases who were diagnosed with breast cancer after giving a blood specimen in 1989-90 were matched to 466 controls in a nested case-control study. NAT2 genotype was determined using PCR-RFLP assays. The multivariate relative risk (RR) comparing slow with rapid acetylators was 0.9 (95% CI 0.7-1.2). Among slow acetylators, current smoking immediately prior to diagnosis was not associated with a significant elevation in risk compared with never smoking rapid acetylators (RR = 1.4, 95% CI 0.7-2.6). No significant association was seen between pack-years of smoking and risk of breast cancer among either slow or fast acetylators. A non-significant elevation in risk was observed among women who smoked for > or = 5 years prior to first pregnancy and were rapid acetylators, compared with never smoking rapid acetylators (RR = 1.5, 95% CI 0.9-2.6). In analyses limited to 706 post-menopausal women, the elevated risks for current smokers immediately prior to diagnosis who were slow acetylators compared with never smokers who were fast acetylators were slightly stronger but still not statistically significant. In summary, we observed little evidence of an association between NAT2 genotype and breast cancer. In this prospective study, cigarette smoking was not appreciably associated with breast cancer among either slow or fast NAT2 acetylators.

[1]  J. Manson,et al.  Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  J. Freudenheim,et al.  Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. , 1996, JAMA.

[3]  E. Negri,et al.  Cigarette smoking and the risk of breast cancer , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  F. Guengerich,et al.  Metabolism of 2-amino-alpha-carboline. A food-borne heterocyclic amine mutagen and carcinogen by human and rodent liver microsomes and by human cytochrome P4501A2. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[5]  J. Alexander,et al.  Effect of acetylator genotype on 3,2'-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. , 1996, Carcinogenesis.

[6]  J Benichou,et al.  Proportion of breast cancer cases in the United States explained by well-established risk factors. , 1995, Journal of the National Cancer Institute.

[7]  D. Bell,et al.  Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. , 1995, Cancer research.

[8]  G. Colditz,et al.  Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[10]  F. Perera,et al.  Carcinogen-DNA adducts in human breast tissue. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[12]  P. Vineis,et al.  Tobacco and cancer: epidemiology and the laboratory. , 1995, Environmental health perspectives.

[13]  J. Benítez,et al.  Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. , 1995, Oncology.

[14]  M A Butler,et al.  Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  Steven R. Tannenbaum,et al.  Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens , 1994, Nature.

[16]  D G Hoel,et al.  Medical hypothesis: xenoestrogens as preventable causes of breast cancer. , 1993, Environmental health perspectives.

[17]  Jack A. Taylor,et al.  Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. , 1993, Carcinogenesis.

[18]  B. Lin,et al.  Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. , 1993, American journal of human genetics.

[19]  J. Russo,et al.  Transformation of human breast epithelial cells by chemical carcinogens. , 1993, Carcinogenesis.

[20]  P. Vineis,et al.  Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. , 1993, European journal of cancer.

[21]  J. Kelsey.  Breast cancer epidemiology: summary and future directions. , 1993, Epidemiologic reviews.

[22]  J L Kelsey,et al.  Breast cancer: magnitude of the problem and descriptive epidemiology. , 1993, Epidemiologic reviews.

[23]  D. Phillips,et al.  Metabolic activation of the food mutagens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) to DNA binding species in human mammary epithelial cells. , 1992, Carcinogenesis.

[24]  S. Shapiro,et al.  Breast cancer and cigarette smoking: a hypothesis. , 1991, American journal of epidemiology.

[25]  K. Ilett,et al.  Acetylation phenotype is not associated with breast cancer. , 1990, Cancer research.

[26]  W. Willett,et al.  Prospective study of smoking and the risk of breast cancer. , 1989, Journal of the National Cancer Institute.

[27]  P. Routledge,et al.  Drug acetylation in breast cancer. , 1989, British Journal of Cancer.

[28]  J. Baron,et al.  Cigarette smoking and breast cancer. , 1989, American journal of epidemiology.

[29]  H. Adami,et al.  Cigarette smoking, alcohol consumption and risk of breast cancer in young women. , 1988, British Journal of Cancer.

[30]  D. Hein.  Acetylator genotype and arylamine-induced carcinogenesis. , 1988, Biochimica et biophysica acta.

[31]  P. Philip,et al.  Acetylator status and its relationship to breast cancer and other diseases of the breast. , 1987, European journal of cancer & clinical oncology.

[32]  G. Grimmer,et al.  Gaschromatographic determination of polycyclic aromatic hydrocarbons, aza-arenes, aromatic amines in the particle and vapor phase of mainstream and sidestream smoke of cigarettes. , 1987, Toxicology letters.

[33]  C. Jara,et al.  Hepatic acetylator polymorphism in breast cancer patients. , 1987, Oncology.

[34]  N E Day,et al.  The design of case-control studies: the influence of confounding and interaction effects. , 1984, International journal of epidemiology.

[35]  M. Pavlova,et al.  Acetylator phenotype in patients with breast cancer. , 1978, Oncology.